Stock Ratings / Health Care / ENLV / insiders

NRSN (38) MDCX (35) RDHL (56) DRMA (43) ⌘ Pro Terminal →

Enlivex Ltd. (ENLV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.54 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.52

Enlivex Ltd. (ENLV) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.52 (-0.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENLV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY ENLV SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 65.3 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.31-29% Next Q

Q2 (-2Q)

Grade E$0.22-9.1% Next Q

Q3 (-1Q)

Grade E$0.20+1170% Next Q

Current

Grade D-$2.54-8.5% Hist 90D α

Trajectory: E (27) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENLV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENLV currently carries a cautious 35/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.85) and Max Pain ($2.67) forces dealer call-delta covering toward $456.12.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENLV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ENLV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ENLV Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ENLV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ENLV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENLV)

✓Walkthrough of ENLV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ENLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.35%⚡ TESTING RESISTANCE

2026-10-30O $2.47H $2.54L $1.73C $2.54VOL 128.2K

RES: $2.56SUP: $0.09SMA50: $0.85SMA200: $8.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENLV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENLV Butterfly Map → + Track ENLV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ENLV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENLV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ENLV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENLV)

Health Care Rank #833 of 1016 ⚔️ NRSN vs ENLV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENLV vs. NRSN, MDCX, RDHL, DRMA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Enlivex Ltd. (ENLV) ranks #833 by composite RQD confidence (35/100, grade D-) and #962 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, ENLV leads on earnings valuation at N/A trailing P/E, while ENLV leads on capital efficiency and profitability with -0.6% ROIC and — gross margin. RDHL currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with ENLV at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ENLV ACTIVE Enlivex Ltd.	D-	35/100	—	—	-0.6%	-2.68%	$3.9M	Benchmark Subject
NRSN NeuroSense Therapeutics Ltd.	D-	38/100	—	—	-35.0%	-9.75%	$4.0M	/nrsn-vs-enlv →
MDCX Medicus Pharma Ltd.	D-	35/100	—	—	-35.0%	-13.31%	$4.1M	/mdcx-vs-enlv →
RDHL Redhill Biopharma Ltd.	D+	56/100	—	—	—	-2.66%	$3.7M	/rdhl-vs-enlv →
DRMA Dermata Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.84%	$4.2M	/drma-vs-enlv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001596812

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enlivex Ltd. (ENLV) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $1.24B, operating cash flow of -$10.4M, and free cash flow of -$10.5M (+20.0% YoY). On the balance sheet, ENLV closed FY2025 with $2.33B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$1.24B	-$10.4M	-$10.5M	$2.33B	—
FY2024 (FY)	2024-12-31	$0	-$15.0M	-$13.0M	-$13.1M	$27.7M	—
FY2023 (FY)	2023-12-31	$0	-$29.1M	-$23.5M	-$23.5M	—	—

3. ENLV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Enlivex Ltd. (NASDAQ: ENLV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $2.54 (-2.68% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ENLV ranks #833 in composite RQD confidence.

How does ENLV compare to NRSN and MDCX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENLV carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -0.6%. By comparison, NRSN (NeuroSense Therapeutics Ltd.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.0M) and MDCX (Medicus Pharma Ltd.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $4.1M). Among the 5-stock peer group, ENLV leads on earnings multiple (N/A) while ENLV leads on capital efficiency (-0.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENLV?

Per ENLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001596812), Enlivex Ltd. generated $0 in revenue, $1.24B in net income, and -$10.5M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENLV trading relative to its 50-day, 200-day, and 52-week technical levels?

ENLV last traded at $2.54 (-2.68% on volume of 50,176 shares), positioning the stock +198.82% above its 50-day simple moving average ($0.85) and -71.40% below its 200-day simple moving average ($8.88). Across its 52-week range of $1.73 to $434.40, ENLV sits at the 0.2% percentile with a 14-day RSI of 65.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.22 to $2.86).

ENLV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ENLV insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ENLV leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ENLV RQD Cockpit ENLV 12M Forecast ENLV Earnings & Move ENLV Dividends & DRIP ENLV Insiders & 13F ENLV Whale Options ENLV Profit Sankey ENLV News & Why